Peyvandi F, Scully M, Kremer HJA, Cataland S, Knöbl P, Wu H, Antoni A, Westwood JP, Mansouri TM, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D, TITAN Investigators. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2016;374:511-22. [Ref.ID 100129]

Ponder KP. Merry Christmas for patients with hemophilia B. N Engl J Med 2011;365:2426-31. [Ref.ID 91983]

Nathwani AC, Tuddenham EGD, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, O'Beirne J, Smith K, Pasi J, Glader B, Rustagi P, Ng CYC, Kay MA, Zhou J, Spence Y, Morton CL, Allay J, Coleman J, Sleep S, Curringham JM, Srivastava D, Basner-Tschakarjan EB, Mingozzi F, High KA, Gray JT, Reiss UM, Nenhuis AW, Davidoff AM. Adenovirus-associated virus vector - Mediated gene transfer in hemophilia B. N Engl J Med 2011;365:2357-65. [Ref.ID 91981]

Anónimo. Prothrombin complex concentrates to reverse warfarin-related bleeding. Med Lett Drugs Ther 2011;53:78-9. [Ref.ID 91712]

Battinelli EM. Reversal of new oral anticoagulants. Circulation 2011;124:1508-10. [Ref.ID 91689]

Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124:1573-9. [Ref.ID 91688]

Kazmi RS, Lwaleed BA. New anticoagulants: how to deal with treatment failure and bleeding complications. Br J Clin Pharmacol 2011;72:593-603. [Ref.ID 91566]

Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J Clin Pharmacol 2011;72:581-92. [Ref.ID 91565]

Toschi V, Lettino M. Inhibitors of propagation of coagulation: factors V and X. Eur J Clin Pharmacol 2011;72:563-80. [Ref.ID 91564]

Franchini M, Mannucci PM. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Eur J Clin Pharmacol 2011;72:553-62. [Ref.ID 91563]

Stevens AJ, Jensen JJ, Wyller K, Kilgore PC, Chatterjee S, Rohrbaugh ML. The role of public-sector research in the discovery of drugs and vaccines. N Engl J Med 2011;364:535-41. [Ref.ID 90172]

Dudzinski DM, Kesselheim AS. Scientific and legal viability of follow-on protein drugs. N Engl J Med 2008;358:843-9. [Ref.ID 82210]

Key NS, Negrier C. Transfusion medicine 3. Coagulation factor concentrates: past, present, and future. Lancet 2007;370:439-48. [Ref.ID 80863]